7QD Stock Chart & Stats
€3.90
-€0.10(-2.50%)
At close: 4:00 PM EDT
€3.90
-€0.10(-2.50%)
Day’s Range― - ―
52-Week Range€1.41 - €4.92
Previous CloseN/A
Volume272.00
Average Volume (3M)20.00
Market Cap
€2.11B
Enterprise Value€2.86K
Total Cash (Recent Filing)€201.32M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Nov 09, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding435,441,350
10 Day Avg. Volume0
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.94
Price to Sales (P/S)0.63
P/FCF Ratio-17.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.81Price Target Upside23.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.05
Revenue Forecast (FY)€2.54B
Bulls Say, Bears Say
Bulls Say
Rapid Membership And Revenue GrowthStrong membership and revenue expansion indicates increasing Medicare Advantage scale and market traction. A larger member base can improve fixed-cost absorption, strengthen operating leverage, and provide more data for Clover’s care-management model over the next several quarters.
Improving Profitability And Self-fundingPositive first-half earnings, substantial liquidity, and no debt give Clover financial flexibility to fund growth internally. This reduces reliance on external capital while allowing continued investment in technology, quality programs, and market density as operations scale.
Cohort Maturation And Focused Technology StrategyThe company’s cohort-based economics and Clover Assistant investment create a potentially repeatable path toward better member performance over time. Concentrating on core markets and retaining underwriting risk may deepen clinical capabilities and capture more upside as cohorts mature.
Bears Say
Profitability Remains Insufficiently DurableDespite recent improvement, Clover has not yet demonstrated consistently profitable full-year operations. Continued sensitivity to medical costs, pricing, and utilization means earnings could remain uneven, limiting confidence that current positive results will persist through a full cycle.
Early-stage Cohorts Pressure Near-term MarginsNearly half of membership is concentrated in cohorts that are still early in the Clover life cycle. Their economics have not fully matured, so near-term margins may remain constrained and the company must execute effectively before expected per-member improvements are realized.
CMS Appeal Creates Stars-related UncertaintyThe favorable Stars recalculation could improve product and bid flexibility, but the pending CMS appeal creates uncertainty around the durability of that advantage. An adverse outcome could affect future payment positioning and complicate planning for benefits, pricing, and growth.
Clover Health Investments News
7QD FAQ
What was Clover Health Investments’s price range in the past 12 months?
Clover Health Investments lowest stock price was €1.41 and its highest was €4.92 in the past 12 months.
What is Clover Health Investments’s market cap?
Clover Health Investments’s market cap is €2.11B.
When is Clover Health Investments’s upcoming earnings report date?
Clover Health Investments’s upcoming earnings report date is Nov 09, 2026 which is in 47 days.
How were Clover Health Investments’s earnings last quarter?
Clover Health Investments released its earnings results on Aug 05, 2026. The company reported €0.043 earnings per share for the quarter, beating the consensus estimate of €0.034 by €0.009.
Is Clover Health Investments overvalued?
According to Wall Street analysts Clover Health Investments’s price is currently Undervalued.
Does Clover Health Investments pay dividends?
Clover Health Investments does not currently pay dividends.
What is Clover Health Investments’s EPS estimate?
Clover Health Investments’s EPS estimate is >-0.01.
How many shares outstanding does Clover Health Investments have?
Clover Health Investments has 435,441,350 shares outstanding.
What happened to Clover Health Investments’s price movement after its last earnings report?
Clover Health Investments reported an EPS of €0.043 in its last earnings report, beating expectations of €0.034. Following the earnings report the stock price went up 8.078%.
Which hedge fund is a major shareholder of Clover Health Investments?
Currently, no hedge funds are holding shares in DE:7QD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clover Health Investments Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.81 (23.29% Upside)
€4.81 (23.29% Upside)
Blogger Sentiment
Bullish
DE:7QD Sentiment 82%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth €90.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Clover Health Investments
Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance. The company leverages its proprietary software platform, the Clover Assistant, to provide both Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) health plans for individuals eligible for Medicare. In addition to its insurance operations, Clover Health also engages in non-insurance-related business ventures. The company was established in 2014 and its main office is located in Franklin, Tennessee.
7QD Company Deck
7QD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong top-line and membership growth (48% MA growth, +56% revenue YoY in Q2), improving profitability (Q2 adjusted EBITDA $41M, GAAP net income $28M), expanded operating leverage, improved cash balance, and a favorable 4.5-star recalculation — all supported by visible cohort maturation dynamics (~$70 PMPM improvement year-over-year between vintages). Manageable lowlights include seasonal Q4 headwinds, a large share of early-stage members that will pressure near-term margins until cohorts mature, ongoing CMS appeal litigation risk, and elevated outpatient trends that require monitoring. Overall, the positive operational and financial momentum, upgraded guidance, and stronger star positioning outweigh the remaining risks and seasonal uncertainties.View all DE:7QD earnings summaries7QD Stock 12 Month Forecast
Average Price Target
€4.81
▲(23.29% Upside)